GUANGZHOU, China–(BUSINESS WIRE)–Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place June 4-8th, 2021.
The presentation, entitled �The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: a multi-center interim analysis will highlight Phase I clinical data demonstrating the safety and efficacy of BG1805, a potent anti-CLL1 CAR-T therapy, in R/R AML pediatric patients. An abstract of the presentation is currently available on ASCO website (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10000).
Presentation details are as follows:
Session Title: |
|
|
| Pediatric Oncology I |
Session Date and Time: |
|
|
| June 5, 2021, 10:00 AM – 1:00 PM |
About Guangzhou Bio-Gene
Guangzhou Bio-Gene is a clinical-stage biopharmaceutical company focused on innovative oncology therapeutics. Bio-Gene is developing a pipeline of autologous and allogeneic CAR-T therapies for the treatment of a broad range of cancers and other diseases. The company is headquartered in Guangzhou, China.
Contacts
Guangzhou Bio-Gene
Guangchao Li, PhD
Senior Director, Business Development
info@gzbiogene.com
www.gzbiogene.com
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 24 March 2025 - Premium travel lifestyle…
GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The…
Six Greater China cities are ranked in the top 20 most expensive office fit out…
SonicWall’s Wide-ranging Platform of Cybersecurity Solutions and Growth with Managed Security Services Providers (MSSPs) Underpin…
New Lenovo agentic AI and hybrid AI factory platforms include NVIDIA Blackwell Ultra support and…
Leverages CTF Group’s Diverse Conglomerate to Address Medical Needs of Families in the Guangdong–Hong Kong–Macau…